Supernus Pharmaceuticals, Inc. $SUPN Stock Position Lifted by Principal Financial Group Inc.

Principal Financial Group Inc. raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 341,117 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,078 shares during the quarter. Principal Financial Group Inc.’s holdings in Supernus Pharmaceuticals were worth $17,632,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SUPN. Rockefeller Capital Management L.P. grew its holdings in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $49,000. Hantz Financial Services Inc. raised its holdings in shares of Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares in the last quarter. Global Retirement Partners LLC raised its holdings in shares of Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 1,182 shares in the last quarter. Finally, Vestcor Inc acquired a new stake in Supernus Pharmaceuticals during the third quarter valued at $67,000.

Supernus Pharmaceuticals Trading Down 1.9%

Supernus Pharmaceuticals stock opened at $46.94 on Thursday. The company has a market capitalization of $2.72 billion, a P/E ratio of -92.04, a P/E/G ratio of 1.02 and a beta of 0.54. The firm’s fifty day simple moving average is $46.63 and its 200-day simple moving average is $49.28. Supernus Pharmaceuticals, Inc. has a 1-year low of $32.51 and a 1-year high of $59.68.

Wall Street Analyst Weigh In

A number of research analysts have commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.